Trial Profile
A Double-blind, Randomized, Placebo-controlled Phase III Trial to Investigate the Efficacy and Safety of NPC-12G Gel (Topical Formulation of Sirolimus) to Angiofibroma and Other Skin Lesions in Patients With Tuberous Sclerosis Complex
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Feb 2017
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary)
- Indications Tuberous sclerosis
- Focus Therapeutic Use
- Sponsors Nobelpharma
- 01 Feb 2017 Status changed from not yet recruiting to completed.
- 25 Dec 2015 New trial record